Now showing items 1-20 of 76

      Citation
      Alpesh AN, Keshishian A, Xie L, Baser O, Price K, Vo L, Singh P, Bruno A, Mardekian J, Tan W, Singhal S, Patel C, Odell K, Trocio J. ( December 5-8, 2015). Early comparison of major bleeding, stroke and associated medical costs among treatment-naive non-valvular atrial fibrillation patients initiating apixaban, dabigatran, rivaroxaban or warfarin. American Society of Hematology (ASH) Annual Meeting and Exposition. Orlando. [oral presentation] [1]
      Amin A, Keshishian A, Xie L, Baser O, Price K, Vo L, Mardekian J, Mendoza M, Singhal S, Patel C, Odell K, Trocio J. (April 2-4, 2016). Real-world comparison of major bleeding risk among untreated non-valvular atrial fibrillation patients and those initiating apixaban, dabigatran, rivaroxaban, or warfarin. American College of Cardiology (ACC) 65th Annual Scientific Session & Expo. San Diego, CA. [1]
      Amin A, Keshishian A, Xie L, Baser O, Price K, Vo L, Mardekian J, Mendoza M, Singhal S, Patel C, Odell K, Trocio J. (August 27-31 , 2016). Real-world comparison of major bleeding and associated costs among treatment-naïve nonvalvular atrial fibrillation patients initiating apixaban or warfarin. European Society of Cardiology (ESC) Congress 2016. Rome, Italy. [1]
      Amin A, Keshishian A, Xie L, Baser O, Price K, Vo L, Singh P, Bruno A, Mardekian J, Tan W, Singhal S, Patel C, Odell K, Trocio J. (November 7-11, 2015). Comparison of major-bleeding risk and health care costs among treatment-naïve non-valvular atrial fibrillation patients initiating apixaban, dabigatran, rivaroxaban, or warfarin. American Heart Association (AHA) Scientific Sessions 2015. Orlando, FL. [1]
      Baser O, Ogbomo A, Tan H, Du J, Xie L. (November 7-11, 2015). Evaluation of the burden of opioid abuse among US veteran patients. International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 18th Annual European Congress. Milan, Italy. [1]
      Baser, O., Kariburyo, MF., Du, J., & Xie, L. (2015). Comparing healthcare resource utilization and costs among schizophrenic patients who initiated typical vs. Atypical long-acting injectables in the us veteran population. Value in Health. 18, 3, p. 119. [1]
      Bashyal R, Du H, Wang L, Baser O. (May 21-25, 2016). Examining the incidence and prevalence of alcohol dependence among US veteran patients. International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 21st Annual International Meeting. Washington DC. [1]
      Bashyal R, Du H, Wang L, Baser O. (May 21-25, 2016). Examining the incidence and prevalence of bipolar disorder among U.S. veteran patients from 2011 to 2015. International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 21st Annual International Meeting. Washington DC. [1]
      Bashyal R, Du H, Wang L, Yuce H, Baser O. (May 21-25, 2016). Examining the mortality and readmission rates of patients diagnosed with stroke in the US Medicare population. International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 21st Annual International Meeting. Washington DC. [1]
      Bashyal R, Du H, Wang L, Yuce H, Baser O. (May 21-25, 2016). Mortality and prevalence of major depressive disorder in the US Medicare population from 2008-2013. International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 21st Annual International Meeting. Washington DC:. [1]
      Black C.M, Hu X, Khandker RK, Ambegaonkar BM, Kariburyo MF, Xie L, Baser O, Yuce H. (July 24-28, 2016). Comparison of all-cause mortality rate and economic burden between newly diagnosed Alzheimer’s disease patients who received anti-dementia treatment versus not: A longitudinal retrospective study. Alzheimer's Association International Conference (AAIC) Annual Conference. Toronto, Canada. [1]
      Cai J, Wang Y, Baser O, Xie L, Diels J, Neslusan C, Chow W. (June 10-14, 2016). Comparative persistence with antihyperglycemic agents (AHA) used to treat type 2 diabetes mellitus (T2DM) in the real world. American Diabetes Association (ADA) 76th Scientific Sessions. New Orleans. [1]
      Cinaroglu, S., & Baser, O. (2016). Understanding the relationship between effectiveness and outcome indicators in health care. Value in Health. 19 Issue: 7 Pages: 495 [1]
      Cinaroglu, S., & Baser, O. (April 01, 2017). Spatial distribution of total number of medical devices in Turkey: A classification analysis. International Journal of Medicine and Public Health, Volume: 19 Issue: 7 Pages: 703 [1]
      Cinaroglu, S., & Baser, O. (January 01, 2016). Socio-economic status and self-rated health: are they good predictors of income? An analysis of survey panel data from turkey. Value in Health, 19, 7. p. 495 [1]
      Cinaroglu, S., & Baser, O. (January 01, 2017). The Role of Stakeholder Engagement in E-Health and the use of Big Data to Predict Health Outcomes. Value in Health, 20 Issue: 9 Pages: A906-A907 [1]
      Cinaroglu, S., Guzel, E., & Baser, O. (2016). The relationship between medical innovation and health expenditures. Value in Health. 19. 7, p. 355-356 [1]
      Fox KM, Wang L, Quek RGW, Gandra SR, Li L, Baser O. (November 7-11, 2015). Long-term increased inpatient and outpatient visits associated with cardiovascular events: A large United States real world study. International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 18th Annual European Congress. Milan, Italy [1]
      Fox, K. M., Wang, L., Gandra, S. R., Quek, R. G., Li, L., & Baser, O. (January 01, 2015). Long-Term Economic Burden Associated With Cardiovascular Events Among High-Risk Patients With Hyperlipidemia. Value in Health, 18, 3.p. 139-140. [1]
      Huang, A., Shrestha, S. & Baser, O.(2015). Health care resource utilizations and costs among migraine patients in the us medicaid population. Value in Health. 18, 3. p.282-283 [1]